ASN Glomerular Diseases – 2023 Update (Videos)
$80.00
Early Program · Nephrology · 2023
International experts deliver the latest evidence on IgA nephropathy, lupus nephritis, membranous nephropathy, FSGS, and ANCA-associated vasculitis through lectures, case discussions, a formal debate, and audience response panels in this focused ASN early program.
-
1program
-
2023year
- Updated treatments for five major glomerular diseases
- Pathology and genetic testing integration
- Glomerular diseases in pregnancy and pediatrics
- Interactive case discussions and formal debate
Glomerular diseases — pathogenesis, diagnosis, and management from international experts
Knowledge about the pathogenesis, diagnosis, and management of glomerular diseases is advancing rapidly, and the ASN glomerular diseases update captures the latest breakthroughs from international experts. This early program uses a dynamic mix of lectures, interactive case-based discussions, a formal debate, self-assessment questions with audience response, and panel discussions to deliver clinical applications that translate directly to patient care.
-
1program
-
2023year
Inside this resource
Treatment updates across major glomerular diseases
Faculty present the latest evidence on treatment protocols for IgA nephropathy, lupus nephritis, membranous nephropathy, FSGS, and ANCA-associated vasculitis. Sessions translate clinical trial results into practical treatment algorithms that clinicians can apply immediately in their practices.
Pathology, classification, and genetic testing
Pathology sessions address classification updates, novel diagnostic criteria, and the integration of genetic testing into glomerular disease evaluation. Faculty demonstrate how pathology findings guide treatment selection and prognosis determination across the disease spectrum.
Special populations and emerging therapies
Dedicated sessions cover glomerular diseases in pregnancy, pediatric populations, and patients with concurrent conditions. Emerging therapies and novel mechanisms of disease are presented through lectures and interactive panels with audience questions.
Interactive learning and audience engagement
The program goes beyond traditional lectures with case-based discussions, a formal debate on controversial topics, self-assessment questions using audience response systems, and open panel discussions that address participant questions in real time throughout the session.
Who this serves
- Nephrologists — managing complex glomerular diseases and selecting evidence-based therapies
- Renal pathologists — integrating pathology findings with clinical management decisions
- Fellows — building foundational knowledge in glomerular disease pathogenesis and treatment
Before you buy
Is this a standalone program?
Yes — this is an ASN Early Program focused exclusively on glomerular diseases, held in conjunction with Kidney Week 2023.
How does this compare to the 2025 Glomerular Diseases update?
Each year features new clinical trial data, updated treatment protocols, and emerging research. The 2023 edition captures the state of the field at that point in time.
The chart
| Format | Early Program |
|---|---|
| Year | 2023 |
| Publisher | American Society of Nephrology |
| Department | Nephrology |
| Delivery | Instant download after checkout · lifetime re-access |
Verified original fileInstant downloadEncrypted checkout
5 reviews for ASN Glomerular Diseases – 2023 Update (Videos)
Add a review
Related products
Nephrology
Nephrology
Nancy L. –
The case-based discussions were the highlight. Real clinical scenarios that tested my knowledge and improved my decision-making.
Steven R. –
Wanted more on complement-mediated diseases — it was covered but not deeply enough. The IgA and lupus content was excellent though.
Patricia W. –
International expert perspectives added depth that single-institution courses cannot match. Outstanding educational program overall.
Thomas J. –
Good balance of pathology and clinical management. The audience response questions kept me engaged throughout the entire program.
Margaret H. –
The debate format was engaging and thought-provoking. Excellent coverage of the latest treatment evidence for glomerular diseases.